BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF^V600E-mutant glioma

Area of Science:

• Neuro-oncology
• Cancer immunology
• Molecular oncology

Background:

• Resistance to BRAF plus MEK inhibitors (BRAFi+MEKi) is a significant challenge in BRAF^V600E-mutant gliomas, leading to tumor progression and poor outcomes.
• The mechanisms underlying this resistance, particularly glioma plasticity, are not well understood.

Purpose of the Study:

• To investigate the mechanisms of BRAFi+MEKi resistance in BRAF^V600E-mutant gliomas.
• To identify potential therapeutic strategies to overcome this resistance.

Main Methods:

• Utilized preclinical mouse models and patient-derived glioma materials.
• Analyzed cell state transitions, immune evasion mechanisms (PD-L1, Galectin-3), and interferon response signatures.
• Evaluated combination therapy of BRAFi+MEKi with immune checkpoint inhibition.

Main Results:

• BRAFi+MEKi treatment induced glioma cell state transitions towards astrocyte- and oligodendrocyte (OL)-like states, contributing to plasticity.
• Upregulation of PD-L1 in OL-like cells was linked to immune evasion and T cell suppression.
• Combination therapy of BRAFi+MEKi with immune checkpoint inhibition significantly improved survival in a T cell-dependent manner.

Conclusions:

• Targeting glioma plasticity and combining BRAFi+MEKi with immune checkpoint inhibitors represent a promising strategy to overcome therapy resistance in BRAF^V600E-mutant high-grade gliomas.
• Elevated PD-L1 in BRAF-mutant gliomas supports the clinical rationale for PD-1 inhibition.